Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Alzheimer Disease

IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials

India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022.

Benzinga

Alzheimer's disease risk increased by picking your nose and plucking hair, warns study

Some habits are seemingly innocent, but some are not only disgusting but could also cause you to unwittingly raise your risk of certain diseases. Case in point: picking your nose

Daily Mirror

Alzheimer's may not be a brain disease

A group of neuroscience researchers think Alzheimer's is an autoimmune condition — could this lead to a cure?

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Alzheimer's disease: surprising new theory about what might cause it

In 1906, Alois Alzheimer, a psychiatrist and neuroanatomist, reported “a peculiar severe disease process of the cerebral cortex” to a gathering of psychiatrists in Tübingen, Germany. The case was a 50-year-old woman who suffered from memory loss, delusions, hallucinations, aggression and confusion – all of which worsened until her untimely…

The Conversation

New Alzheimer's drug that slows cognitive decline could be available next year

People who are prescribed the drug will need regular MRI scans to check for brain swelling or bleeding

Wales Online

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

The Conversation

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Texas researchers receive $149 million for large study of Alzheimer’s in racial, ethnic groups

FORT WORTH, Texas — The National Institutes of Health is giving $149 million to researchers at the University of North Texas Health Science Center to pay for researchers to study the biology of Alzheimer’s disease in multiple racial and ethnic groups.

Tribune News Service

Alzheimer's risk increased by 80% in over 65s who have had Covid, claims study

Experts are still unclear as to whether Covid can trigger the onset of Alzheimer's or speed its development.

Daily Record

Over-65s twice as likely to develop Alzheimer’s within a year of Covid infection, according to study

Researchers from the Case Western Reserve University in Cleveland, Ohio analysed the electronic health records of 6.2 million adults

Evening Standard

Covid warning to everyone aged 66 and above

New research has found over 65s who contract covid increase their risk of getting Alzheimer's

Liverpool Echo

Having had Covid can increase risk of Alzheimer's by 80% for some people

Researchers aren't certain whether COVID-19 triggers new development of Alzheimer’s disease or accelerates its emergence

Wales Online

Over-65s who had Covid are 80 per cent more likely to develop Alzheimer’s, study reveals

It is unclear whether coronavirus triggers new development of the disease or accelerates its emergence

The Independent UK

‘Historic moment’: Drug slows cognitive decline in Alzheimer’s

It's being widely reported that an experimental drug has slowed the cognitive decline and brain damage in Alzheimer's patients.

The New Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

Wales Online

Drug shown to slow memory decline in Alzheimer's patients in 'historic' breakthrough

Alzheimer's Research UK said this is the first later-stage trial of an Alzheimer's drug 'in a generation' to successfully slow cognitive decline

Daily Record

Alzheimer's drug is world's first shown to slow symptoms in 'historic' breakthrough

The success of an experimental drug offers new hope to people affected by the cruel disease.

Evening Standard

‘Historic’ breakthrough as dementia drug shown to slow cognitive decline

Lecanemab found to slow decline in participants’ memory and thinking caused by the brain-wasting disease by 27 per cent

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Mirror

World's first EVER drug shown to work against Alzheimer's developed by scientists

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Wales Online

Major breakthrough for dementia and Alzheimer's as drug found to reduce decline

Alzheimer’s Research UK said the finding was a “historic moment for dementia research”

The Independent UK

‘Major breakthrough’ as dementia drug found to ‘slow cognitive decline’

The new clinical trial found that there was a significant reduction in the decline in memory and thinking usually seen in early-stage patients.

Dynamite News

Health: Study finds Alzheimer's disease risk connected to newly discovered protein

According to a new USC study, a mutation in a newly discovered small protein is connected to a significant increase in the risk for Alzheimer's disease, expanding the known gene targets for the disease and presenting a new potential avenue for treatment. Read more on Dynamite News:

Daily Record

The simple steps to help prevent Alzheimer's and keep your brain active and healthy

Here's some helpful advice if you are worried about dementia or are supporting a loved one who is suffering.

Benzinga

IGC Announces Issuance Of Second Patent For The Treatment Of Alzheimer's Using THC

India Globalization Capital, Inc. (AMEX:IGC) announced that the United States Patent and Trademark Office issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”

The Conversation

Alzheimer’s might not be primarily a brain disease. A new theory suggests it’s an autoimmune condition.

The pursuit of a cure for Alzheimer’s disease is becoming an increasingly competitive and contentious quest with recent years witnessing several important controversies.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University College London

193 stories

USF

191 stories

Alzheimer Research UK

152 stories

National Institutes of Health

Karolinska Institutet

48 stories

Alzheimer Scotland

27 stories

Case Western Reserve University

16 stories

IGC

16 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.